We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world. https://lnkd.in/dj5gBmkF
Leap Therapeutics’ Post
More Relevant Posts
-
TOS) has just completed enrollment for its Phase 2 EVANGELINE clinical trial, evaluating (Z)-endoxifen for ER+ / HER2- breast cancer. Plus, insider buying signals strong confidence in the company's future! 💰 Want to get in on this trade? Check out our recommended buy levels, target prices, and stop loss details. With a potential upside of 27% to 53%, this $1 stock offers 2x to 3x more potential upside than downside! #Investment #StockMarket #AtossaTherapeutics #Biopharma #TradingTips #StrongBuy
Atossa Therapeutics (ATOS): A $1 Stock with Massive Upside Potential?
caribbeanemagazine.com
To view or add a comment, sign in
-
Informative feed back from Oncology Clinical Development community of challenges and ways to navigate toward success. #clinical #oncology #biomarker #precision #pipeline #strategy
ICON’s recent survey of oncology drug development professionals reveals the scale of focus on precision therapies. Partnership and collaboration with industry partners will be critical to navigating an increasingly diverse, sophisticated and crowded oncology landscape. Read more on how sponsors can adapt to this highly competitive market: https://ow.ly/AXM250TlLpp
To view or add a comment, sign in
-
Thoughts on this? >> Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing
Merck, Daiichi detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy
endpts.com
To view or add a comment, sign in
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/ke9V30sE80Y #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/9LzH30sCZjg #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/yfRL30sE2Z0 #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/12fo30sCYK0 #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
Setting realistic expectations for how payer coverage is likely to build over time is critical for pharma companies. https://ow.ly/UAB250SjbFW In this case study, learn how one small oncology biopharma used MMIT’s coverage uptake analysis for new drugs to prepare for the launch of its therapy. #FDA #Oncology #Biopharma #BiopharmaInsights #MarketAccess
To view or add a comment, sign in
-
Trust the experts who have propelled over 500 oncology projects in 2021. Discover how Certara's biosimulation and regulatory strategy expertise can accelerate your path to success for your oncology drug program. Learn more: https://ow.ly/k92A50P9Y1y
Accelerating Oncology DrugDevelopment with Biosimulation andRegulatory Strategy
To view or add a comment, sign in
-
The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB
The antibody–drug conjugate landscape
nature.com
To view or add a comment, sign in
5,217 followers